All In Biotech

Drug Trial Radar · NCT03718065

Impact of Lofexidine on Stress, Craving and Opioid Use

Last checked: Nov 20, 2026Latest source record: Feb 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 112 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

112

Actual

Start

Jun 26, 2019

Primary completion

Jan 30, 2024

Study completion Jan 30, 2024

Sponsor

Lead sponsor
Medical University of South CarolinaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institutes of Health (NIH); National Institute on Drug Abuse (NIDA)
First posted
Oct 24, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Individuals with opioid use disorder who are stabilized on buprenorphine or methadone will be randomly assigned to receive placebo or lofexidine for 5 weeks. At the end of five weeks, they will complete a human laboratory stress task and scripted opioid imagery task. Throughout the study a CREMA app (Cue Reactivity Ecological Momentary Assessment) will be used to monitor stress, craving and use in the natural environment.

Conditions

  • Opioid-use Disorder
  • Opiate Dependence

Interventions

  • LofexidineDrug

    Lofexidine, sold under the brand name Lucemyra among others, is a medication historically used to treat high blood pressure, but more commonly used to help with the physical symptoms of opioid withdrawal. It is taken by mouth. It is an α2A adrenergic receptor agonist.

  • PlaceboDrug

    Placebo comparator.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Drug Cue+ Stressor Induced CravingTime frame: Pre- Cue and 0, 5, 30 and 60 minutes Post-Cue 5 weeks Post- Baseline; Pre-TSST and 0, 5, 30 and 60 minutes Post-TSST 5 weeks Post-Baseline
  2. Drug Cue+ Stressor Induced Stress ResponseTime frame: Pre- Cue and 0, 5, 30 and 60 minutes Post-Cue 5 weeks Post- Baseline; Pre-TSST and 0, 5, 30 and 60 minutes Post-TSST 5 weeks Post-Baseline

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Medical University of South Carolina

    Charleston, South Carolina

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.